1064O ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer (EOC): Final overall survival (OS) analysis
Clamp, Andrew McNeish, Iain Radice, Domenico Lord, Rosemary Michael, Agnieszka Cook, Audrey Agarwal, Roshan Walther, Axel Blagden, Sarah O'Donnell, Dearbhaile
Clamp, Andrew
McNeish, Iain
Radice, Domenico
Lord, Rosemary
Michael, Agnieszka
Cook, Audrey
Agarwal, Roshan
Walther, Axel
Blagden, Sarah
O'Donnell, Dearbhaile
Glos Author
Date
2025-11-05
Journal Title
Subject
Type
Journal Article
Collections
Abstract
No abstract available
Citation
Clamp et al (2025). 1064O ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy+ bevacizumab to three-weekly chemotherapy+ bevacizumab in high-risk stage III-IV epithelial ovarian cancer (EOC): Final overall survival (OS) analysis. Annals of Oncology, 36, S712-S713.